Drug
Lonafarnib clinical trials
Also written SCH66336, Sarasar and EBP994.
- studies test it
- 27
- open now
- 1
- in phase 3
- 4
- first study started
- 1999
Keep track of what changes. Save the lonafarnib studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- LNF
- 2
Brand
Studies by the year they started
27 studies that test it; most in 2002 (3)
| Year | Studies |
|---|---|
| 1999 | 2 |
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 2 |
| 2004 | 2 |
| 2005 | 3 |
| 2006 | 2 |
| 2007 | 2 |
| 2008 | 1 |
| 2009 | 1 |
| 2011 | 1 |
| 2015 | 3 |
| 2018 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 12
- Phase 2
- 13
- Phase 3
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 6 · Other 21
M.D. Anderson Cancer Center (7) · Merck Sharp & Dohme LLC (4) · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (3) · Boston Children's Hospital (2) · European Organisation for Research and Treatment of Cancer - EORTC (2) · EIT Pharma, Inc. (1) · Soroka University Medical Center (1) · Eiger BioPharmaceuticals (1)
Often tested with
Tested in the same studies.
Ritonavir (5) · Temozolomide (4) · Docetaxel (2) · Peginterferon alfa-2a (1) · Zoledronic Acid (1) · Pravastatin (1) · Imatinib (1) · Trastuzumab (1)
Studies
Open first, then newest update. How each study uses lonafarnib is read from its arms, and is right about nine times in ten.
Testing it · 27
- Phase I/II Trial of Everolimus in Combination With Lonafarnib in ProgeriaEnrolling by invitationPhase 1/2Boston Children's HospitalNCT02579044Written as Everolimus and lonafarnib
- Titrating-Dose of Lonafarnib in Combination With RitonavirCompletedPhase 2EIT Pharma, Inc.NCT02527707Written as lonafarnib
- Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus InfectionCompletedPhase 3Soroka University Medical CenterNCT05229991Written as Lonafarnib
- Lonafarnib and Temozolomide in Treating Patients with Glioblastoma Multiforme That is Recurrent or Did Not Respond to Previous Treatment with TemozolomideActive, not recruitingPhase 1M.D. Anderson Cancer CenterNCT00102648Written as Lonafarnib
- Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2aCompletedPhase 3Eiger BioPharmaceuticalsNCT03719313Written as Lonafarnib
- Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda InterferonCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT03600714Written as Lonafarnib
- Phase II Trial of Lonafarnib (a Farnesyltransferase Inhibitor) for ProgeriaCompletedPhase 2Monica E. KleinmanNCT00425607Written as Lonafarnib
- A Study of Zoledronic Acid, Pravastatin, and Lonafarnib for Patients With ProgeriaCompletedPhase 2Boston Children's HospitalNCT00879034Written as Lonafarnib
- 4-HPR and FTI in Head and Neck Squamous Cell Carcinoma (HNSCC)TerminatedPhase 1M.D. Anderson Cancer CenterNCT00102635Written as SCH66336
- SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the LiverWithdrawnPhase 1M.D. Anderson Cancer CenterNCT00005030Written as SCH 66336
- Study of Lonafarnib and Gleevec in Chronic Myelogenous LeukemiaCompletedPhase 1M.D. Anderson Cancer CenterNCT00047502Written as Lonafarnib (SCH66336)
- A Phase IB Study Of Oral SCH 66336 Preoperatively In Patients With Head And Neck Squamous Cell CancerCompletedPhase 1M.D. Anderson Cancer CenterNCT00038584Written as SCH66336
- Phase II Study of SCH66336, A Farnesyltransferase Inhibitor in Chronic Myelogenous Leukemia (CML)CompletedPhase 2M.D. Anderson Cancer CenterNCT00038597Written as SCH66336
- Temozolomide and SCH66336 for Recurrent Glioblastoma MultiformeCompletedPhase 2M.D. Anderson Cancer CenterNCT00038493Written as Temozolomide and SCH66336
- Treatment of Chronic Delta Hepatitis With Lonafarnib and RitonavirCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT02511431Written as Lonafarnib
- Lonafarnib for Chronic Hepatitis DCompletedPhase 2National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)NCT01495585Written as Lonafarnib
- Lonafarnib in Metastatic Breast CancerTerminatedPhase 2George SledgeNCT00773474Written as Lonafarnib
- Study of Lonafarnib in Combination With Paclitaxel and Carboplatin in Patients With Non-Small Cell Lung Cancer (Study P01901)(TERMINATED)TerminatedPhase 3Merck Sharp & Dohme LLCNCT00050336Written as Lonafarnib (SARASAR)
- Study of Lonafarnib Versus Placebo in Subjects With Either Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) (Study P02978AM3)(TERMINATED)TerminatedPhase 3Merck Sharp & Dohme LLCNCT00109538Written as Lonafarnib
- Anastrozole Plus Lonafarnib (SCH 66336) or Plus Placebo for the Treatment of Advanced Breast Cancer (P03480)CompletedPhase 2Merck Sharp & Dohme LLCNCT00081510Written as Lonafarnib
See all 27 studies that test lonafarnib →
Given in every arm · 4 — lonafarnib is usual care beside what is tested
- Study to Determine Optimal Dose and Evaluate Safety, Tolerability, and Pharmacokinetics of Progerinin in Patients With Hutchinson-Gilford Progeria Syndrome (HGPS)CompletedPhase 2PRG Science & Technology Co., Ltd.NCT06775041Written as Lonafarnib
- Lonafarnib Boosted With Ritonavir With and Without Peginterferon Alfa-2a (PEG IFN-a) in HDV (LOWR-2)CompletedPhase 2EIT Pharma, Inc.NCT02430194Written as lonafarnib
- Lonafarnib With and Without Ritonavir in HDV (LOWR-1)CompletedPhase 2EIT Pharma, Inc.NCT02430181Written as lonafarnib
- A Study of Lonafarnib With or Without Ritonavir in Patients With HDVWithdrawnPhase 2Eiger BioPharmaceuticalsNCT02968641Written as Lonafarnib
Codes
What other systems call lonafarnib · ClinicalTrials.gg INT004112
- MeSH (NLM) C115354lonafarnibConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) IOW153004FLONAFARNIBConfirmed FDA, NLM, Wikidata
- RxNorm 2467553One source FDA
- Wikidata Q3258910lonafarnibConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C1829LonafarnibOne source FDA
- DrugBank DB06448One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C115354 | lonafarnib | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | IOW153004F | LONAFARNIB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2467553 | — | One source FDA |
| Wikidata | Q3258910 | lonafarnib | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C1829 | Lonafarnib | One source FDA |
| DrugBank | DB06448 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.